1211399-74-4

Basic information

• Product Name: 4-Chloro-2-Methylpyridin-3-aMine
• Synonyms: 4-Chloro-2-Methylpyridin-3-aMine
• CAS NO: 1211399-74-4
• Molecular Formula: C6H7ClN2
• Molecular Weight: 142.58618
• Mol File: 1211399-74-4.mol

Chemical Properties

• Boiling Point: 248.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.260±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.79±0.10(Predicted)
• CAS DataBase Reference: 4-Chloro-2-Methylpyridin-3-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-2-Methylpyridin-3-aMine(1211399-74-4)
• EPA Substance Registry System: 4-Chloro-2-Methylpyridin-3-aMine(1211399-74-4)

Safety Data

• Hazardous Substances Data: 1211399-74-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-chloro-2-methylpyridin-3-amine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its presence in the molecular composition allows for the development of new therapeutic agents with specific pharmacological properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-chloro-2-methylpyridin-3-amine is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties enable the creation of effective compounds that can protect crops from pests and enhance agricultural productivity.
Used in the Synthesis of Niclosamide:
4-chloro-2-methylpyridin-3-amine is specifically used as a crucial component in the creation of Niclosamide, an anthelmintic drug. It serves as an essential building block for the development of this medication, which is used to treat tapeworm infections in both humans and animals, highlighting its importance in the field of parasitology and veterinary medicine.

Upstream product

• 357263-45-7 2-bromo-4-chloropyridin-3-amine 
• 823-96-1 Trimethylboroxine 
• 20511-15-3 3-amino-4-chloropyridine 

Relevant articles and documents

HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.

SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smoantagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.